GRS and CORRONA enter strategic partnership for clinical research in rheumatoid arthritis

Nov 8 2010

Global Research Services, LLC (GRS), an international full-service clinical research organization (CRO), and The Consortium of Rheumatology Researchers of North America, Inc. (CORRONA), the largest independent initiative for clinical research in rheumatoid arthritis, announced today their strategic partnership to bring together Phase I-IV clinical research capabilities with the largest rheumatology patient registry in North America.

"CORRONA's explosive growth in the rheumatic disease therapeutic area is based on rigorous data, our high quality investigator database, and over 30,000 enrolled subjects, all areas which continue to increase. Our efforts and scientific reputation have resulted in over 130 sponsor publications since the year 2000. Business and industry have propelled us to expand our capabilities in clinical research in diverse global geographic locations where GRS has an established presence," stated Dr. Joel Kremer, President and CEO, CORRONA.

"The GRS and CORRONA partnership offers enormous benefits to clients by providing access to a world class global CRO with a 25-year proven track record, well-trained staff and established processes and procedures for efficient conduct of clinical trials with the largest, validated observational database of RA treatment patterns and outcomes in the US. Together we offer faster start up and subject enrollment, leading to shorter time to market," commented Dr. Bruce Garrett, President and CEO, GRS.